Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (November 13, 2026) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, toda

Event · Earnings
Original reporting
Published Nov 13, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$INDP
Bullish
medium confidence
Mentioned
$INDP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INDPBullishMed
01

Why it matters

The filing updates traders on (1) capital raised and proceeds timing, (2) cash and short-term investments available as of Sept. 30, and (3) quantified reductions in R&D and G&A expenses, which together inform funding runway and near-term risk.

02

Market read

Traders can reassess INDP’s liquidity runway and burn-rate trajectory immediately based on the disclosed cash position and expense declines, while factoring dilution and preclinical uncertainty.

03

What to watch

Termination fee from the ATM agreement and the relatively small R&D spend mean the burn-rate improvement may reflect reduced activity rather than improved clinical prospects.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Nov. 13, 2026

Background

Indaptus is a biotech focused on its Decoy immunotherapy platform and is evaluating additional early-stage initiatives, including a neurotechnology concept for sleep-related conditions.

Company-level read

Ticker impact

$INDPBullishMedium confidence
Context

Indaptus reports Q3 2026 financial results and discloses a completed $24.0 million private placement plus updated liquidity and R&D cost reductions.

Expected impact

Likely modest upward bias as the market prices improved liquidity and lower burn, partially offset by dilution/early-stage pipeline uncertainty.

Evidence & confidence

The filing includes concrete proceeds received, cash and short-term investments as of Sept. 30, and quantified expense declines, all of which directly affect funding runway and near-term valuation risk.

Market effects

Reinforces the ongoing biotech pattern of financing to fund early-stage programs, with investors focusing on runway and burn-rate changes.

Limited, company-specific impact for a Nasdaq-listed micro-cap biotech.

Low, no cross-market policy or sector-wide shock indicated.

Counterpoint

The private placement improves cash but also signals ongoing financing needs, and the new neurotechnology device remains preclinical with uncertain timelines.

Key entities

  • Indaptus Therapeutics, Inc.

    Nasdaq-listed biotech that filed an 8-K with Q3 2026 results and a corporate update including a $24.0 million private placement.

  • Private placement (Sept. 8, 2026; closed Oct. 16, 2026)

    20,338,974 shares sold for aggregate gross proceeds of approximately $24.0 million, with most proceeds received by Sept. 30 and remainder in October.

  • Decoy20 Phase 1 study

    Clinical cost driver referenced as contributing to lower R&D expenses in Q3 2026.

Related articles

$INDPMed

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (August 13, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today

$INDPMedAI 8/10

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics (Nasdaq: INDP) reported Q2 2026 results and a corporate update. It raised about $12.0 million via a June 17 private placement at $0.60 per share. The company discontinued further Decoy20 enrollment and has no active clinical programs. Q2 R&D fell to ~$0.4M and net loss to ~$1.8M. Cash and short-term investments were ~$11.6M at June 30.

$CISSMedAI 8/10

C3is (CISS) Q3 2026 Earnings Call Transcript

C3is (CISS) reported Q3 2026 earnings, with voyage revenues up 249% YoY to $16.7M and nine-month revenues up 116% to $52.4M. Adjusted net income increased 1,300% YoY to $13.2M. Cash balance rose 335% to $64.9M. The company expanded its fleet and secured time charters for bulk carriers. Management highlighted strong market demand for iron ore, coal, and grain, driving shipping rates.

$NVDAHighAI 9/10

What's Going On With Nvidia Stock Wednesday

Nvidia (NVDA) reported quarterly earnings of $2.68 per share on revenue of $115.84 billion, beating estimates. Data center sales reached $107.6 billion. The company raised its revenue forecast for the current quarter and long-term growth outlook, but expects no revenue from China. Nvidia also expanded its stock buyback program.